Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain

Purpose

Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.

Conditions

  • Chronic Low-back Pain
  • Vertebrogenic Pain Syndrome

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU). - Signed a valid, IRB/EC-approved informed consent form.

Exclusion Criteria

  • Meets any contraindications per locally applicable Instructions for Use (IFU).

Study Design

Phase
Study Type
Observational [Patient Registry]
Observational Model
Cohort
Time Perspective
Prospective

Arm Groups

ArmDescriptionAssigned Intervention
Intracept™ Intraosseous Nerve Ablation Systems Subjects with pain treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System
  • Device: Intracept™ Intraosseous Nerve Ablation
    Intracept™ Intraosseous Nerve Ablation for treatment of patients diagnosed with vertebrogenic pain

Recruiting Locations

Flagstaff Bone & Joint
Flagstaff, Arizona 86001
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

Innovative Pain and Wellness
Phoenix, Arizona 85014
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

MarinHealth Spine Institute
Larkspur, California 94939
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

Stanford University Medical Center
Stanford, California 94305
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

The Spine Wellness Center in Westport
Westport, Connecticut 06880
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

Washington Hospital Center
Washington D.C., District of Columbia 20010
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

Orlando Regional Medical Center
Orlando, Florida 32806
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

Horizon Clinical Research, LLC
Jasper, Georgia 30143
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

Illinois Bone and Joint Institute
Barrington, Illinois 60010
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

Commonwealth Pain and Spine
Lexington, Kentucky 40509
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

Ochsner Clinic Foundation
New Orleans, Louisiana 70115
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

iSpine Clinics
Maple Grove, Minnesota 55369
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

CentraCare Health System
Saint Cloud, Minnesota 56303
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

New York Spine and Pain Specialists
Port Jefferson Station, New York 11776
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

University of Rochester
Rochester, New York 14618
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

Novant Health Spine Specialists
Bermuda Run, North Carolina 27106
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

Allegheny General Hospital
Pittsburgh, Pennsylvania 15212
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

Cy-Pain and Spine
Houston, Texas 77065
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

University of Utah Orthopaedic Center
Salt Lake City, Utah 84108
Contact:
Boston Scientific Clinical Research
855-213-9890
BSNClinicalTrials@bsci.com

More Details

Status
Recruiting
Sponsor
Boston Scientific Corporation

Study Contact

Ann Yamano
855-213-9890
BSNClinicalTrials@bsci.com

Detailed Description

The objective of this study is to compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.